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The third issue of volume two of Therapeutics and Clinical Risk Management presents
review articles and original research papers on a wide range of topics.
World Health Organisation guidelines indicate morphine use for control of
moderate-to-severe pain in chronic cancer based on factors such as accessibility,
effectiveness, ease of administration, and cost as opposed to its being therapeutically
superior. Survey data from the Research Network of the European Association for
Palliative Care indicate that opioid rotation may achieve more effective pain control
with fewer side effects than single usage alone. Oxycodone is a member of the opioid
class with high oral-to-parenteral bioavailability with no threshold in its analgesic
effect. Giuseppe Biancofiore examines the pharmacokinetics and pharmacodynamics
of oxycodone and reviews a selection of studies examining its efficacy and safety
profile in the treatment of cancer pain.
Considerable evidence exists to support the use of the bisphosphonate alendronate
sodium in the management of osteoporosis. Prinsloo and Hosking comprehensively
discuss the fracture intervention trial (FIT), a major grouping of four pivotal studies
that demonstrated alendronate’s efficacy and provided the foundation for subsequent
clinical trials and a range of post-hoc analyses. The two studies of the vertebral
fracture arm, the clinical fracture arm and the osteoporotic cohort are all critically
evaluated in depth and the results expanded upon in the discussion of the prevention
of multiple fractures, prediction of responses to treatment, and aspects of primary
prevention. In addition, the authors present data relating to the role of alendronate in
the management of male osteoporosis and in corticosteroid-induced osteoporosis.
Mucositis-related pain is one of the primary side effects of cancer treatment with
approximately 40% of chemotherapy patients and most patients undergoing bone
marrow transplant affected. Despite the plethora of current therapies, none is especially
specific to or effective in mucositis. Debra Harris reviews recent advances in our
knowledge of pain management in mucositis including its pathophysiology, clinical
manifestations and the strengths and weaknesses of the respective assessment tools
including the Harris mucositis-related pain assessment tool that is specific to mucosal
pain and contains dimensions of pain; functional ability; and effectiveness of
interventions. Although the tool is as yet unvalidated it contains numerous validated
elements from other assessment methods. The author concludes with a range of key
recommendations aimed at standardising assessment, classification and patient
treatment in a mucositis-specific manner.
Cervical cancer is the second most common malignancy amongst females
worldwide. In their overview Winters et al examine the role of vaccination against
human papilloma virus by highlighting a range of recent studies considered to be of
greatest relevance to cervical cancer. Their approach includes discussion of pathology,
epidemiology and current prevention strategies and treatment. Furthermore the authors
examine studies of vaccines in development, prophylactic vaccines and some relevant
associated contentious issues.
Bortezomib is a novel proteasome inhibitor whose introduction heralds a major
advance in the management of multiple myeloma and as first-line therapy prior to
stem cell transplantation. Bortezomib is notable for its positive response in the
previously refractory patient and enhanced survival rates in the relapsed patient,
data that led to its approval by regulators in the US in 2003 and in Europe in 2005. In
this review, Antonia Field-Smith and colleagues present a comprehensive overview
of findings from Phase II/Phase III clinical trials and address its clinical use, includingTherapeutics and Clinical Risk Management 2006:2(2) 228
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side effects and toxicity; management of associated
peripheral neuropathy (which affects 30% to 40% of
patients) and thrombocytopenia. Finally, the authors give a
comprehensive overview of bortezomib in combination with
other chemotherapeutic agents and conclude that it is
effective when administered in the outpatient setting.
A range of management strategies exists which can
attenuate the sequelae of age-related osteoporosis.
MacLaughlin et al review the background to the topic and
discuss epidemiology and economic impact, diagnosis and
classification together with an analysis of the intrinsic and
extrinsic risk factors for fall-related fractures. In addition,
they provide information on the respective roles of many
pharmacological therapies including: calcium and vitamin
D; the bisphosphonates; calcitonin; estrogen receptor
stimulators; strontium ranelate; sodium fluoride; and
teriparatide.
Secondary hyperparathyroidism (SHPT) is a serious
clinical outcome of chronic renal disease. The renal
impairment-associated decline in active vitamin D
(calcitriol) is critically linked to the development of SHPT
and its allied cardiovascular complications. While
intravenous vitamin D analogues such as paricalcitol are
routinely used in hemodialysis patients, the US FDA
approved a novel oral paricalcitol preparation for use in pre-
chronic kidney disease in 2005. Cheng and Coyne review
the data underpinning oral paricalcitrol and consider its
potential long-term benefits for reduced hospitalizations and
enhanced survival and include a brief discussion of its
emerging role in the attenuation of vascular calcification,
atherosclerosis and renal fibrosis.
Migraine is a prevalent condition predominantly
affecting females with approximately half of these being
susceptible to menstrual headache onset. This may last
longer and demonstrate greater resistance to treatment than
other forms of migraine. Frovatriptan, a 5-HT receptor
agonist, is a second-generation triptan with a
pharmacokinetic profile of proven benefit in the
management of menstrual migraine. Ebrahim Balbisi
reviews its pharmacology and pharmacokinetics and
discusses the clinical efficacy, safety and tolerability of
frovatriptan in the treatment of this common and distressing
condition.
Non-standard prescribing practices have been found to
play a significant role in the under-utilisation of
anticoagulant drugs. The technique of academic detailing
aims to enhance prescribing behavior and has been used
successfully in both community and hospital environments.
Roberts and Adams examined the effects of introducing
guidelines based on academic detailing on initiation of
warfarin therapy, reversal of warfarin over anticoagulation,
and uptake of deep vein thrombosis phrophylaxis in four
teaching hospitals. The authors report that use of academic
detailing enhanced guideline roll-out, produced positive
results in the majority of areas studied and was well-received
by prescribing practitioners.
Small-cell lung cancer (SCLC) has a poor prognosis
associated with significant morbidity, mortality and
economic cost. Although several novel, third-generation
chemotherapeutic drugs are available for SCLC treatment,
their cost effectiveness have yet to be fully determined. Uyl-
de Groot and colleagues have developed a Markov chain
model for the projection of patient outcome parameters and
associated costs in SCLC for patients treated with either
etoposide–cisplatin combination therapy or a hypothetical
new drug. They conclude that increased future costs for
SCLC treatment will result in only a relatively minor
extension of survival time. However, both palliation and
quality of life parameters should also be enhanced and the
authors predict enhanced outcome and cost-effectiveness
with emerging treatment regimens.
Psoriasis therapy represents a substantial healthcare
expenditure that was previously estimated at $1.6bn–3.2bn
in the US alone; the recent emergence of 3 novel biologic
response modifiers has significantly increased this
projection. Cost-utility analysis (CUA) utilises quality-
adjusted life years (QALYs) as an effectiveness endpoint
and between US$50–100 000 is considered an affordable
therapeutic intervention. Weiss et al used Euro-Qol 5
Dimension (EQ5D), an instrument that has been
standardized for the description and evaluation of health
states, in order to formulate a preliminary CUA of psoriasis
therapy. The authors conclude that current psoriasis
therapeutics confer comparable utilities relative to those in
other medical specialties.
Gastroesophageal reflux disease (GERD) is a highly
prevalent, unpleasant and debilitating condition
characterized by heartburn and regurgitation of food, the
latter being association with Barrett’s esophagus and
adenocarcinoma of the esophagus and gastric cardia. Nowak
and colleagues conducted a retrospective case series study
of 23 adult patients who attended a dietetic clinic for lifestyle
intervention in the management of GERD.  The authors
report that 22 patients reported an improvement in their
symptoms and noted a reduction in medication usage
amongst 11 of the 18 patients who had been taking GERD
medication at time of presentation.  In spite of the small
number of patients studied, their results indicate further
evaluation of the role of lifestyle modification in GERD is
warranted.